Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.59 |
| ▸ | NAMPT | P43490 | 4/20 | 0.44 |
| ▸ | ACACB | O00763 | 3/20 | 0.44 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30329030 | 0.89 | EIF2AK4 (0.47) | CYP11B2GPR119CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30328216 | 0.87 | EIF2AK4 (0.51) | CYP11B2NAMPTGPR119CYP3A4CYP2D6 | |
| SCHEMBL2423408 | 0.85 | GPR119 (0.55) | GPR119ALDH1A1 | |
| SCHEMBL13156810 | 0.85 | CYP11B2 (0.61) | CYP11B2NAMPTACACBSCD5GPR119 | |
| SCHEMBL30329134 | 0.83 | NAMPT (0.45) | CYP11B2NAMPTACACBGPR119HDAC2 | |
| SCHEMBL31700957 | 0.81 | CYP11B2 (0.60) | CYP11B2NAMPTACACBSCD5GPR119 | |
| SCHEMBL484892 | 0.81 | CYP11B2 (0.57) | CYP11B2NAMPTACACBSCD5HDAC2 | |
| SCHEMBL19693453 | 0.81 | CYP11B2 (0.57) | CYP11B2NAMPTACACBSCD5GPR119 | |
| SCHEMBL484102 | 0.81 | HIF1A (0.63) | CYP11B2CYP3A4CYP2D6CYP2C9HIF1A | |
| SCHEMBL13156818 | 0.80 | CYP11B2 (0.56) | CYP11B2NAMPTACACBHDAC2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| US-8455475-B2 | Substituted spiro-amide compounds | GRUENENTHAL GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| EP-2411381-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | CYP11B2 2150/4885NAMPT 2232/4885ACACB 4258/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | CYP11B2 2150/4885NAMPT 2232/4885ACACB 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.